Evidence map›Paper›PMID 41233438›Full record

ArticleScientific reports2025

Proteomics characterization of triple-negative apocrine carcinoma reveals molecular features of progression and chemotherapy response.

Yiying Zhu, Mengping Long, Wenhao Shi, Tianlong He, Fangzhou Xie, Annan Qian, Yuqiao Liu, Taobo Hu, Shaojun Tang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yiying Zhu *Department of Chemistry, Tsinghua University, Beijing, 100084, China. yiying_zhu@mail.tsinghua.edu.cn.
Mengping Long *Department of Breast Surgery, Peking University People's Hospital, Beijing, 100044, China.
Wenhao Shi *Department of Chemistry, Tsinghua University, Beijing, 100084, China.
Tianlong He *Bioscience and Biomedical Engineering Thrust, The Hong Kong University of Science and Technology (Guangzhou), Guangzhou, 511453, China.
Fangzhou XieBioscience and Biomedical Engineering Thrust, The Hong Kong University of Science and Technology (Guangzhou), Guangzhou, 511453, China.
Annan QianBioscience and Biomedical Engineering Thrust, The Hong Kong University of Science and Technology (Guangzhou), Guangzhou, 511453, China.
Yuqiao LiuBioscience and Biomedical Engineering Thrust, The Hong Kong University of Science and Technology (Guangzhou), Guangzhou, 511453, China.
Taobo HuDepartment of Pathology, Peking University Cancer Hospital, Beijing, 100083, China. thuac@connect.ust.hk.
Shaojun TangBioscience and Biomedical Engineering Thrust, The Hong Kong University of Science and Technology (Guangzhou), Guangzhou, 511453, China. shaojuntang@ust.hk.

Funding

National Natural Science Foundation of China 82202068Peking University Cancer Hospital PY202331
6 · The paper itself

Abstract

Triple-negative apocrine carcinoma (TNAC) is a rare and chemotherapy-insensitive subtype of triple-negative breast cancer (TNBC), characterized by specific morphology and molecular features. Despite limited chemotherapy response, TNAC shows favorable long-term survival, suggesting distinct resistance mechanisms. In this study, we present the first proteomics-based profiling of TNAC formalin-fixed paraffin-embedded (FFPE) samples using mass spectrometry. Our analysis reveals progressive activation of PI3K/AKT and androgen receptor (AR) signaling, along with upregulation of GTPase-related proteins, suggesting enhanced invasiveness. Post-chemotherapy TNAC displays increased inflammation and mixed ribosomal regulation, pointing to a metabolic shift in survival strategy. These findings support the rationale for exploring chemotherapy de-escalation strategies in TNAC, and highlight the potential utility of PI3K/AKT inhibitors and AR antagonists, possibly in combination with GTPase inhibitors, metabolic disruptors, or immunotherapy.

Indexed as

Apocrine GlandsProteomicsTriple Negative Breast NeoplasmsDisease ProgressionFemaleHumansMiddle AgedPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptors, AndrogenSignal TransductionPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptors, Androgen

Identifiers

PMID41233438
PMCPMC12615654

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.